The relevance of the metabolic syndrome

Annals of the Academy of Medicine Singapore

Volumn 38, Issue 1, 2009, Pages 29-33

  Taslim, Siska ^a   Shyong Tai, E ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Cardiovascular disease; Diabetes mellitus; Insulin resistance; Obesity

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID;

BEHAVIOR THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; HEALTH CARE DELIVERY; HEALTH SERVICE; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; LIFESTYLE MODIFICATION; MEDLINE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SCORING SYSTEM; THERAPY EFFECT;

EID: 60049084391     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
2. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Geneva: World Health Organization, 1999.
3. Expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (2001) Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
4. Alberti KG, Zimmet P, Shaw J, the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005;366:1059-62.
5. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the new International Diabetes Federation. Diabet Med 2006;23:469-80.
6. Gundy AM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
7. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. A summary of the evidence. Diabetes Care 2005;28:1769-78.
8. Heng D, Ma S, Lee J, Tai BC, Mak KH, Hughes K, et al. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischaemic heart disease. Atherosclerosis 2006;186:367-73.
9. Lee J, Heng D, Ma S, Chew SK, Hughes K, Tai ES. The metabolic syndrome and mortality: the Singapore Cardiovascular Cohort Study. Clin Endocrinol (Oxf) 2008;69:225-30.
10. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004;27:2676-81.
11. Wannamethee SG, Sharper AG, Lennon L, Moris RW. Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005;165:2644-50.
12. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005;28:385-390.
13. Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D'Agostino RB et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004;94:20-4.
14. Barzi F, Patel A, Gu D, Sritara P, Lam TH, Rodgers A, et al. Asia Pacific Cohort Studies Collaboration. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health 2007;61:115-21.
15. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-7.
16. Stern MP, Williams K, Haffner SM. Identification ofpersons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 2002;136:575-81.
17. Aekplakorn W, Bunnag P, Woodward M, Sritara P, Cheepudomwit S, Yamwong S, et al. A risk score for predicting incident diabetes in the Thai population. Diabetes Care 2006;29:1872-7.
18. Lindstrom J, Tuomilehto J. The diabetes risk score. A practical tool to predict type 2 diabetes risk. Diabetes Care 2003;26:725-731.
19. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005;48:1684-99.
20. Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev 2002;3:141-6.
21. Araneta MR, Barrett-Connor E. Ethnic differences in visceral adipose tissue and type 2 diabetes: Filipino, African-American, and white women. Obes Res 2005;13:1458-65.
22. Kadowaki T, Sekikawa A, Murata K, Maegawa H, Takamiya T, Okamura T, et al. Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study. Int J Obes (Lond) 2006;30:1163-5.
23. Lear SA, Humphries KH, Kohli S, Birmingham CL. The use of BMI and waist circumference as surrogates of body fat differs by ethnicity. Obesity (Silver Spring) 2007;15:2817-24.
24. Khoo CM, Liew CF, Chew SK, Tai ES. The impact of central obesity as a prerequisite for the diagnosis of the metabolic syndrome. Obesity (Silver Spring) 2007;15:262-9.
25. Lee J, Ma S, Heng D, Tan CE, Chew SK, Hughes K, et al. Should central obesity be an optional or essential component ofthe metabolic syndrome? Diabetes Care 2007;30:343-7.
26. Lien LF, Brown AJ, Ard JD, Loria C, Erlinger TP, Feldstein AC, et al. Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension 2007;50:609-16.
27. Pyorala K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ et al, for the Scandinavian Simvastatin Survival Study Group. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome. Diabetes Care 2004;27:1735-40.
28. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly D, Haffner SM, et al. Metabolic syndrome with and without c-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9.
29. Deedwania P, Barter P, Carmena R, Fruchart J, Grundy S M, Haffner S, et al. For the Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006;368:919-28.
30. Schwartz G, Olsson A, Szarek M, Sashela W. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome. An analysis of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care 2005;28:2508-13.
31. Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-27.
32. Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006;97:477-9.
33. The BIP Study Group. Secondary Prevention by Raising HDL Cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000;102:21-7.
34. Tenenbaum A, Motro M, Fisman E, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165:1154-60.
35. Wilkin T. The Metabolic syndrome, babies and bathwater. Diabetologia 2006;49:421-2.